# A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ≥18 and &lt;45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)

Study · id `cardio:ct-nct01814748` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01814748](<https://clinicaltrials.gov/study/NCT01814748>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01814748

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 203 participants.

## Technical summary

Registry record NCT01814748. Randomized; double masking; primary purpose treatment. Start 2013-05-03 (actual); primary completion 2015-09-14 (actual). Results posted on 2016-07-18.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 203 participants (enrolled count; ClinicalTrials.gov record NCT01814748, source copy `cardio:ctgov-nct01814748-2018-09-10`, retrieved 2026-10-26)
- Started: 2013-05-03 (actual) (ClinicalTrials.gov record NCT01814748, source copy `cardio:ctgov-nct01814748-2018-09-10`, retrieved 2026-10-26)
- Primary completion: 2015-09-14 (actual) (ClinicalTrials.gov record NCT01814748, source copy `cardio:ctgov-nct01814748-2018-09-10`, retrieved 2026-10-26)
- Completion: 2015-09-14 (actual) (ClinicalTrials.gov record NCT01814748, source copy `cardio:ctgov-nct01814748-2018-09-10`, retrieved 2026-10-26)
- Results first posted: 2016-07-18 (ClinicalTrials.gov record NCT01814748, source copy `cardio:ctgov-nct01814748-2018-09-10`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01814748-2018-09-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ≥18 and &lt;45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)
- Condition: Diabetes Mellitus
- Intervention (Drug): Omarigliptin
- Intervention (Drug): Placebo to omarigliptin
- Intervention (Drug): Metformin
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Use of Prohibited Medication, a Potentially Overlooked Confounder in Clinical Trials: Omarigliptin (Once-weekly DPP-4 Inhibitor) Monotherapy Trial in 18- to 45-year-olds (`cardio:pubmed-28923291`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: d943d0d9eb3c6669bdf75f949e9286cf9ee64849fa825c21f7aee62786859c0d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
